{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:12:42Z","timestamp":1769296362527,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001790","name":"Ara Parseghian Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["24POST1193887"],"award-info":[{"award-number":["24POST1193887"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["24POST1191688"],"award-info":[{"award-number":["24POST1191688"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jbc.2025.110370","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T08:05:56Z","timestamp":1750061156000},"page":"110370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Itraconazole and posaconazole, inhibitors of NPC1 sterol transport, act as pharmacological chaperones after washout"],"prefix":"10.1016","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6714-7600","authenticated-orcid":false,"given":"Weixiang A.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-3926","authenticated-orcid":false,"given":"Cheng-I.J.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-522X","authenticated-orcid":false,"given":"Noah","family":"Steinfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-8866","authenticated-orcid":false,"given":"Frederick R.","family":"Maxfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.110370_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1471-4159.2010.06976.x","article-title":"Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches","volume":"116","author":"Rosenbaum","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jbc.2025.110370_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","article-title":"Niemann-Pick disease type C","volume":"64","author":"Vanier","year":"2003","journal-title":"Clin. Genet."},{"key":"10.1016\/j.jbc.2025.110370_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/jcm9030679","article-title":"Molecular genetics of niemann-pick type C disease in Italy: an update on 105 patients and description of 18 NPC1 novel variants","volume":"9","author":"Dardis","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jbc.2025.110370_bib4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/302626","article-title":"Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype","volume":"65","author":"Millat","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2025.110370_bib5","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1074\/jbc.M708735200","article-title":"Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding","volume":"283","author":"Gelsthorpe","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110370_bib6","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1073\/pnas.0914309107","article-title":"Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells","volume":"107","author":"Rosenbaum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110370_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006951","article-title":"Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression","volume":"4","author":"Davidson","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2025.110370_bib8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1194\/jlr.M700525-JLR200","article-title":"Genetic variations and treatments that affect the lifespan of the NPC1 mouse","volume":"49","author":"Liu","year":"2008","journal-title":"J. Lipid. Res."},{"key":"10.1016\/j.jbc.2025.110370_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010101","article-title":"Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease","volume":"7","author":"Vite","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2025.110370_bib10","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/jimd.12428","article-title":"Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2\/3 trial of a novel treatment","volume":"44","author":"Mengel","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.jbc.2025.110370_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100114","article-title":"HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts","volume":"62","author":"Pipalia","year":"2021","journal-title":"J. Lipid. Res."},{"key":"10.1016\/j.jbc.2025.110370_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1194\/jlr.M072140","article-title":"Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells","volume":"58","author":"Pipalia","year":"2017","journal-title":"J. Lipid. Res."},{"key":"10.1016\/j.jbc.2025.110370_bib13","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1073\/pnas.1014890108","article-title":"Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts","volume":"108","author":"Pipalia","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110370_bib14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1021\/acsptsci.1c00033","article-title":"Inhibition of histone deacetylases 1, 2, and 3 enhances clearance of cholesterol accumulation in niemann-pick C1 fibroblasts","volume":"4","author":"Cruz","year":"2021","journal-title":"ACS. Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jbc.2025.110370_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.chembiol.2013.02.009","article-title":"Discovery of oxysterol-derived pharmacological chaperones for NPC1: implication for the existence of second sterol-binding site","volume":"20","author":"Ohgane","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jbc.2025.110370_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243746","article-title":"Image-based screen capturing misfolding status of Niemann-Pick type C1 identifies potential candidates for chaperone drugs","volume":"15","author":"Shioi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2025.110370_bib17","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jbc.2025.110370_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1358\/dot.2015.51.12.2421058","article-title":"Triazole antifungals: a review","volume":"51","author":"Peyton","year":"2015","journal-title":"Drugs. Today. (Barc)"},{"key":"10.1016\/j.jbc.2025.110370_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1073\/pnas.1619571114","article-title":"Triazoles inhibit cholesterol export from lysosomes by binding to NPC1","volume":"114","author":"Trinh","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110370_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1379\/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2","article-title":"Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein","volume":"1","author":"Brown","year":"1996","journal-title":"Cell. Stress. Chaperones."},{"key":"10.1016\/j.jbc.2025.110370_bib21","doi-asserted-by":"crossref","first-page":"ar62","DOI":"10.1091\/mbc.E21-11-0578","article-title":"Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants","volume":"33","author":"McDonald","year":"2022","journal-title":"Mol. Biol. Cell."},{"key":"10.1016\/j.jbc.2025.110370_bib22","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jbc.2025.110370_bib23","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.jbc.2025.110370_bib24","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid \u03b2-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110370_bib25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.jbc.2025.110370_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01184-19","article-title":"Low central nervous system posaconazole concentrations during cerebral phaeohyphomycosis","volume":"63","author":"Barde","year":"2019","journal-title":"Antimicrob. Agents. Chemother."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825022203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825022203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:46:03Z","timestamp":1761147963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825022203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0021925825022203"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110370","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Itraconazole and posaconazole, inhibitors of NPC1 sterol transport, act as pharmacological chaperones after washout","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"110370"}}